Business Description
DarioHealth Corp
NAICS : 325413
SIC : 3841
ISIN : US23725P1003
Description
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.25 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.61 | |||||
| Beneish M-Score | -4.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.4 | |||||
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 23.8 | |||||
| 3-Year FCF Growth Rate | 28.6 | |||||
| 3-Year Book Growth Rate | -14.9 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.23 | |||||
| 9-Day RSI | 59.94 | |||||
| 14-Day RSI | 53.51 | |||||
| 6-1 Month Momentum % | 4.48 | |||||
| 12-1 Month Momentum % | -53.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.79 | |||||
| Quick Ratio | 3.38 | |||||
| Cash Ratio | 2.95 | |||||
| Days Inventory | 158.93 | |||||
| Days Sales Outstanding | 77.91 | |||||
| Days Payable | 44.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.6 | |||||
| Shareholder Yield % | -26.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.4 | |||||
| Operating Margin % | -276.09 | |||||
| Net Margin % | -292 | |||||
| FCF Margin % | -152.14 | |||||
| ROE % | -83.32 | |||||
| ROA % | -54.3 | |||||
| ROIC % | -93.2 | |||||
| ROC (Joel Greenblatt) % | -1262.37 | |||||
| ROCE % | -60.95 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.07 | |||||
| PB Ratio | 0.69 | |||||
| Price-to-Tangible-Book | 3.61 | |||||
| EV-to-EBIT | -0.62 | |||||
| EV-to-EBITDA | -0.68 | |||||
| EV-to-Forward-EBITDA | -2.35 | |||||
| EV-to-Revenue | 1.79 | |||||
| EV-to-Forward-Revenue | 0.64 | |||||
| EV-to-FCF | -1.17 | |||||
| Price-to-Net-Current-Asset-Value | 4.48 | |||||
| Earnings Yield (Greenblatt) % | -161.29 | |||||
| FCF Yield % | -70.51 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers